The results of a preclinical study have identified a biological mechanism that explains why some patients don’t respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors. The study, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback